Your browser doesn't support javascript.
loading
Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.
Glykofridis, Iris E; Knol, Jaco C; Balk, Jesper A; Westland, Denise; Pham, Thang V; Piersma, Sander R; Lougheed, Sinéad M; Derakhshan, Sepide; Veen, Puck; Rooimans, Martin A; van Mil, Saskia E; Böttger, Franziska; Poddighe, Pino J; van de Beek, Irma; Drost, Jarno; Zwartkruis, Fried Jt; de Menezes, Renee X; Meijers-Heijboer, Hanne Ej; Houweling, Arjan C; Jimenez, Connie R; Wolthuis, Rob Mf.
Afiliação
  • Glykofridis IE; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Knol JC; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Balk JA; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Westland D; University Medical Center Utrecht, Center for Molecular Medicine, Molecular Cancer Research, Universiteitsweg, Utrecht, Netherlands.
  • Pham TV; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Piersma SR; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Lougheed SM; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Derakhshan S; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan, Utrecht, Netherlands.
  • Veen P; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Rooimans MA; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • van Mil SE; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Böttger F; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Poddighe PJ; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Amsterdam, Netherlands.
  • van de Beek I; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Amsterdam, Netherlands.
  • Drost J; Princess Máxima Center for Pediatric Oncology, Oncode Institute, Heidelberglaan, Utrecht, Netherlands.
  • Zwartkruis FJ; University Medical Center Utrecht, Center for Molecular Medicine, Molecular Cancer Research, Universiteitsweg, Utrecht, Netherlands.
  • de Menezes RX; NKI-AvL, Biostatistics Unit, Amsterdam, Netherlands.
  • Meijers-Heijboer HE; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Houweling AC; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Amsterdam, Netherlands.
  • Jimenez CR; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Wolthuis RM; Amsterdam UMC, location VUmc, Vrije Universiteit Amsterdam, Clinical Genetics, Cancer Center Amsterdam, Amsterdam, Netherlands.
Elife ; 102021 01 18.
Article em En | MEDLINE | ID: mdl-33459596
Germline mutations in the Folliculin (FLCN) tumor suppressor gene cause Birt-Hogg-Dubé (BHD) syndrome, a rare autosomal dominant disorder predisposing carriers to kidney tumors. FLCN is a conserved, essential gene linked to diverse cellular processes but the mechanism by which FLCN prevents kidney cancer remains unknown. Here, we show that disrupting FLCN in human renal tubular epithelial cells (RPTEC/TERT1) activates TFE3, upregulating expression of its E-box targets, including RRAGD and GPNMB, without modifying mTORC1 activity. Surprisingly, the absence of FLCN or its binding partners FNIP1/FNIP2 induces interferon response genes independently of interferon. Mechanistically, FLCN loss promotes STAT2 recruitment to chromatin and slows cellular proliferation. Our integrated analysis identifies STAT1/2 signaling as a novel target of FLCN in renal cells and BHD tumors. STAT1/2 activation appears to counterbalance TFE3-directed hyper-proliferation and may influence immune responses. These findings shed light on unique roles of FLCN in human renal tumorigenesis and pinpoint candidate prognostic biomarkers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Transporte / Proteínas Proto-Oncogênicas / Proteínas Supressoras de Tumor / Células Epiteliais / Rim Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Transporte / Proteínas Proto-Oncogênicas / Proteínas Supressoras de Tumor / Células Epiteliais / Rim Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda